Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
Clinical trial NCT04401800 · COMPLETED
Trial details
- NCT number
- NCT04401800
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-04
- Primary completion
- 2022-12-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.